Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

被引：27

作者：

Fink, A. M. ^{[1
,2
,15
,16
]}

Bottcher, S. ^{[3
,15
,16
]}

Ritgen, M. ^{[3
]}

Fischer, K. ^{[1
,2
]}

Pflug, N. ^{[1
,2
]}

Eichhorst, B. ^{[1
,2
]}

Wendtner, C-M ^{[1
,2
]}

Winkler, D. ^{[4
]}

Buhler, A. ^{[4
]}

Zenz, T. ^{[4
,5
,6
,7
]}

Staib, P. ^{[8
]}

Mayer, J. ^{[9
,10
,11
]}

Hensel, M. ^{[5
,6
,7
]}

Hopfinger, G. ^{[12
]}

Wenger, M. ^{[13
]}

Fingerle-Rowson, G. ^{[1
,2
]}

Dohner, H. ^{[4
]}

Kneba, M. ^{[3
]}

Stilgenbauer, S. ^{[4
]}

Busch, R. ^{[14
]}

Hallek, M. ^{[1
,2
]}

机构：

[1] Dept Internal Med 1, Cologne, Germany

[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

[3] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[4] Klinikum Munchen Schwabing, Munich, Germany

[5] Univ Ulm, Dept Internal Med 3, Ulm, Germany

[6] Natl Ctr Tumor Dis NCT, Dept Translat Oncol, Heidelberg, Germany

[7] German Canc Res Ctr, Heidelberg, Germany

[8] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[9] St Antonius Hosp Eschweiler, Klin Hamatol & Onkol, Eschweiler, Germany

[10] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[11] Masaryk Univ, CEITEC, Brno, Czech Republic

[12] Mannheimer Onkol Praxis, Mannheim, Germany

[13] Hanusch Hosp Vienna, Dept Med 3, Vienna, Austria

[14] Paracelsus Med Univ, Dept Med 3, Salzburg, Austria

[15] F Hoffmann Roche Ltd, Pharmaceut Div, Basel, Switzerland

[16] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany

来源：

LEUKEMIA | 2013年 / 27卷 / 09期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL; QUANTIFICATION; PROGRESSION;

D O I：

10.1038/leu.2013.190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1949 / +

页数：5

共 15 条

[1] Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
Boettcher, S.
Stilgenbauer, S.
Busch, R.
Brueggemann, M.
Raff, T.
Pott, C.
Fischer, K.
Fingerle-Rowson, G.
Doehner, H.
Hallek, M.
Kneba, M.
Ritgen, M.
[J]. LEUKEMIA, 2009, 23 (11) : 2007 - 2017
[2] Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Boettcher, Sebastian
Ritgen, Matthias
Fischer, Kirsten
Stilgenbauer, Stephan
Busch, Raymonde M.
Fingerle-Rowson, Guenter
Fink, Anna Maria
Buehler, Andreas
Zenz, Thorsten
Wenger, Michael Karl
Mendila, Myriam
Wendtner, Clemens-Martin
Eichhorst, Barbara F.
Doehner, Hartmut
Hallek, Michael J.
Kneba, Michael
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 980 - 988
[3] The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
Dicker, F.
Herholz, H.
Schnittger, S.
Nakao, A.
Patten, N.
Wu, L.
Kern, W.
Haferlach, T.
Haferlach, C.
[J]. LEUKEMIA, 2009, 23 (01) : 117 - 124
[4] Genomic aberrations and survival in chronic lymphocytic leukemia.
Döhner, H
Stilgenbauer, S
Benner, A
Leupolt, E
Kröber, A
Bullinger, L
Döhner, K
Bentz, M
Lichter, P
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) : 1910 - 1916
[5] Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
Dreger, P.
Corradini, P.
Kimby, E.
Michallet, M.
Milligan, D.
Schetelig, J.
Wiktor-Jedrzejczak, W.
Niederwieser, D.
Hallek, M.
Montserrat, E.
[J]. LEUKEMIA, 2007, 21 (01) : 12 - 17
[6] Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
Gonzalez, David
Martinez, Pilar
Wade, Rachel
Hockley, Sarah
Oscier, David
Matutes, Estella
Dearden, Claire E.
Richards, Sue M.
Catovsky, Daniel
Morgan, Gareth J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2223 - 2229
[7] Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Hallek, M.
Fischer, K.
Fingerle-Rowson, G.
Fink, A. M.
Busch, R.
Mayer, J.
Hensel, M.
Hopfinger, G.
Hess, G.
von Gruenhagen, U.
Bergmann, M.
Catalano, J.
Zinzani, P. L.
Caligaris-Cappio, F.
Seymour, J. F.
Berrebi, A.
Jaeger, U.
Cazin, B.
Trneny, M.
Westermann, A.
Wendtner, C. M.
Eichhorst, B. F.
Staib, P.
Buehler, A.
Winkler, D.
Zenz, T.
Boettcher, S.
Ritgen, M.
Mendila, M.
Kneba, M.
Doehner, H.
Stilgenbauer, S.
[J]. LANCET, 2010, 376 (9747) : 1164 - 1174
[8] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Hallek, Michael
Cheson, Bruce D.
Catovsky, Daniel
Caligaris-Cappio, Federico
Dighiero, Guillaume
Doehner, Hartmut
Hillmen, Peter
Keating, Michael J.
Montserrat, Emili
Rai, Kanti R.
Kipps, Thomas J.
[J]. BLOOD, 2008, 111 (12) : 5446 - 5456
[9] Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
Oscier, David
Wade, Rachel
Davis, Zadie
Morilla, Alison
Best, Giles
Richards, Sue
Else, Monica
Matutes, Estella
Catovsky, Daniel
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (10): : 1705 - 1712
[10] Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
Pettitt, Andrew R.
Jackson, Richard
Carruthers, Stacey
Dodd, James
Dodd, Susanna
Oates, Melanie
Johnson, Gillian G.
Schuh, Anna
Matutes, Estella
Dearden, Claire E.
Catovsky, Daniel
Radford, John A.
Bloor, Adrian
Follows, George A.
Devereux, Stephen
Kruger, Anton
Blundell, Julie
Agrawal, Samir
Allsup, David
Proctor, Stephen
Heartin, Earnest
Oscier, David
Hamblin, Terry J.
Rawstron, Andrew
Hillmen, Peter
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1647 - 1655

← 1 2 →